Emerging Treatment Options for Multi-Drug-Resistant Bacterial Infections
Antimicrobial resistance (AMR) remains one of the top public health issues of global concern. Among the most important strategies for AMR control there is the correct and appropriate use of antibiotics, including those available for the treatment of AMR pathogens. In this article, after briefly revi...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-06-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/11/6/519 |
| _version_ | 1797531554705047552 |
|---|---|
| author | Roberto Giurazza Maria Civita Mazza Roberto Andini Pasquale Sansone Maria Caterina Pace Emanuele Durante-Mangoni |
| author_facet | Roberto Giurazza Maria Civita Mazza Roberto Andini Pasquale Sansone Maria Caterina Pace Emanuele Durante-Mangoni |
| author_sort | Roberto Giurazza |
| collection | DOAJ |
| description | Antimicrobial resistance (AMR) remains one of the top public health issues of global concern. Among the most important strategies for AMR control there is the correct and appropriate use of antibiotics, including those available for the treatment of AMR pathogens. In this article, after briefly reviewing the most important and clinically relevant multi-drug-resistant bacteria and their main resistance mechanisms, we describe the emerging antimicrobial options for both MDR Gram-positive cocci and Gram-negative bacilli, including recently marketed agents, molecules just approved or under evaluation and rediscovered older antibiotics that have regained importance due to their antimicrobial spectrum. Specifically, emerging options for Gram-positive cocci we reviewed include ceftaroline, ceftobiprole, tedizolid, dalbavancin, and fosfomycin. Emerging treatment options for Gram-negative bacilli we considered comprise ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, aztreonam-avibactam, minocycline, fosfomycin, eravacycline, plazomicin, and cefiderocol. An exciting scenario is opening today with the long awaited growing availability of novel molecules for the treatment of AMR bacteria. Knowledge of mechanisms of action and resistance patterns allows physicians to increasingly drive antimicrobial treatment towards a precision medicine approach. Strict adherence to antimicrobial stewardship practices will allow us to preserve the emerging antimicrobials for our future. |
| first_indexed | 2024-03-10T10:45:25Z |
| format | Article |
| id | doaj.art-f521c3dc667647bb81d6cd1c0eabd9be |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-10T10:45:25Z |
| publishDate | 2021-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-f521c3dc667647bb81d6cd1c0eabd9be2023-11-21T22:38:49ZengMDPI AGLife2075-17292021-06-0111651910.3390/life11060519Emerging Treatment Options for Multi-Drug-Resistant Bacterial InfectionsRoberto Giurazza0Maria Civita Mazza1Roberto Andini2Pasquale Sansone3Maria Caterina Pace4Emanuele Durante-Mangoni5Department of Precision Medicine, University of Campania ‘L. Vanvitelli’, Internal Medicine Section, Piazzale Ettore Ruggieri snc, 80131 Naples, ItalyDepartment of Precision Medicine, University of Campania ‘L. Vanvitelli’, Internal Medicine Section, Piazzale Ettore Ruggieri snc, 80131 Naples, ItalyUnit of Infectious and Transplant Medicine, AORN Ospedali dei Colli-Monaldi Hospital, Piazzale Ettore Ruggieri snc, 80131 Naples, ItalyDepartment of Woman, Child and General & Specialized Surgery, University of Campania ‘L. Vanvitelli’, Piazza Miraglia, 80138 Naples, ItalyDepartment of Woman, Child and General & Specialized Surgery, University of Campania ‘L. Vanvitelli’, Piazza Miraglia, 80138 Naples, ItalyDepartment of Precision Medicine, University of Campania ‘L. Vanvitelli’, Internal Medicine Section, Piazzale Ettore Ruggieri snc, 80131 Naples, ItalyAntimicrobial resistance (AMR) remains one of the top public health issues of global concern. Among the most important strategies for AMR control there is the correct and appropriate use of antibiotics, including those available for the treatment of AMR pathogens. In this article, after briefly reviewing the most important and clinically relevant multi-drug-resistant bacteria and their main resistance mechanisms, we describe the emerging antimicrobial options for both MDR Gram-positive cocci and Gram-negative bacilli, including recently marketed agents, molecules just approved or under evaluation and rediscovered older antibiotics that have regained importance due to their antimicrobial spectrum. Specifically, emerging options for Gram-positive cocci we reviewed include ceftaroline, ceftobiprole, tedizolid, dalbavancin, and fosfomycin. Emerging treatment options for Gram-negative bacilli we considered comprise ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, aztreonam-avibactam, minocycline, fosfomycin, eravacycline, plazomicin, and cefiderocol. An exciting scenario is opening today with the long awaited growing availability of novel molecules for the treatment of AMR bacteria. Knowledge of mechanisms of action and resistance patterns allows physicians to increasingly drive antimicrobial treatment towards a precision medicine approach. Strict adherence to antimicrobial stewardship practices will allow us to preserve the emerging antimicrobials for our future.https://www.mdpi.com/2075-1729/11/6/519antimicrobial resistancebrand-new antibioticsold revived antibioticsplace in therapydrug therapyextensively drug resistant |
| spellingShingle | Roberto Giurazza Maria Civita Mazza Roberto Andini Pasquale Sansone Maria Caterina Pace Emanuele Durante-Mangoni Emerging Treatment Options for Multi-Drug-Resistant Bacterial Infections Life antimicrobial resistance brand-new antibiotics old revived antibiotics place in therapy drug therapy extensively drug resistant |
| title | Emerging Treatment Options for Multi-Drug-Resistant Bacterial Infections |
| title_full | Emerging Treatment Options for Multi-Drug-Resistant Bacterial Infections |
| title_fullStr | Emerging Treatment Options for Multi-Drug-Resistant Bacterial Infections |
| title_full_unstemmed | Emerging Treatment Options for Multi-Drug-Resistant Bacterial Infections |
| title_short | Emerging Treatment Options for Multi-Drug-Resistant Bacterial Infections |
| title_sort | emerging treatment options for multi drug resistant bacterial infections |
| topic | antimicrobial resistance brand-new antibiotics old revived antibiotics place in therapy drug therapy extensively drug resistant |
| url | https://www.mdpi.com/2075-1729/11/6/519 |
| work_keys_str_mv | AT robertogiurazza emergingtreatmentoptionsformultidrugresistantbacterialinfections AT mariacivitamazza emergingtreatmentoptionsformultidrugresistantbacterialinfections AT robertoandini emergingtreatmentoptionsformultidrugresistantbacterialinfections AT pasqualesansone emergingtreatmentoptionsformultidrugresistantbacterialinfections AT mariacaterinapace emergingtreatmentoptionsformultidrugresistantbacterialinfections AT emanueledurantemangoni emergingtreatmentoptionsformultidrugresistantbacterialinfections |